Trial Profile

Disitamab Vedotin RC-48 Combined With Zimberelizumab GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer A Single-arm, Open-label, Phase II Clinical Trail RIGHT Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Disitamab vedotin (Primary) ; Zimberelimab (Primary)
Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
Focus Adverse reactions; Therapeutic Use
Acronyms RIGHT; RIGHT Study

21 Jan 2023 Trial design, presented at the 2023 Gastrointestinal Cancers Symposium
16 Sep 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com